Detect DNA and RNA variants as well as biomarker signatures, such as TMB and MSI, for multiple solid tumor types. Generate a comprehensive genomic profile of a patient's tumor to support treatment decisions according to clinical guidelines.
Content includes key biomarkers associated with drug labels, ESMO recommendations and clinical trials, for multiple solid tumor types. Test results help inform therapy decisions according to clinical guidelines.
Offer precision oncology in your institution, keep data in-house and avoid losing samples to send-out services. Internalizing CGP potentially enables your lab to increase the number of informed cases you provide.
TruSight Oncology Comprehensive (EU) offers cancer patients and healthcare providers the ability to help unlock treatment options and help match patients with promising genomically matched therapy regimens. Learn how this IVD test can empower you to be an active voice in making therapy decisions that may improve the patient's journey.View Video
TruSight Oncology Comprehensive (EU) generates a single actionable report with information on 500+ biomarkers in just 4-5 days. Conventional tests often require separate tests and several weeks to obtain reports for a small number of biomarkers.
TruSight Oncology Comprehensive (EU) provides coverage of multiple variant classes from DNA and RNA and genomic signatures like TMB and MSI in coding exons in a large panel of cancer-related genes. Small panels cover fewer genes and less of the coding sequence and may miss actionable alterations.
|Other Solid Tumors||ALK||APC||BCOR||BRAF||BRCA1||BRCA2||CDK4||CIC||CTNNB1||DNAJB1||ERBB2||ERG|
Genes listed in this table represent a subset of all genes present in the panel and include genes with biomarkers of clinical significance linked to current drug labels or guidelines. For a full gene list, refer to the product data sheet or package insert. Content analysis provided by PierianDx, based on IVD software Knowledge Base v6.5 (September 2021).
Rely on a CE-marked IVD sample-to-answer solution that can be implemented easily, empowering you to generate test results quickly and accurately.
Fully automated sequencing and data analysis
See TruSight Oncology Comprehensive (EU) product specifications, available configurations and accessories, and initiate an order online. Take the next step to begin offering this test in your institution.Request Pricing
In this educational video, our healthcare experts discuss the evolution in cancer therapies and how precision medicine, through comprehensive genomic profiling testing, is poised to become the new standard of care.
Our physicians, scientists, and product development experts discuss how this new comprehensive genomic profiling test provides extensive content to cover the key biomarkers that can help inform therapy selection decisions for cancer patients.
A comprehensive support program is available to expedite implementation and certification and ensure a smooth integration. The program provides laboratory training, including wet-lab instruction and run assessment, a verification protocol, and 24/5 technical support.
Onboarding plan to expedite test verification
Laboratory training, including wet-lab instruction and assessment run
Verification protocol provided
VIP portal for sharing educational and marketing assets by Illumina
Technical support available 24/5
Content in TruSight Oncology Comprehensive will continue to evolve as new discoveries are made. Illumina has partnered with multiple established pharma companies to develop a growing pipeline of companion diagnostic indications.
All companion diagnostic tests are currently under development. Availability of each companion diagnostic test is subject to receipt of appropriate regulatory approvals, variable timelines, and geography.
Looking for more details on how TruSight Oncology Comprehensive (EU) can benefit your lab? Find detailed specifications and a sample clinical report here.
Healthcare experts worldwide discuss how CGP can lead to more efficiencies in a pathology lab operation, as well as increase the likelihood of finding actionable biomarkers